Market Insight from

How could vaccine hesitancy affect the prevalence of hearing disorders?

Hearing disorders are a common cause of disability and affect an estimated 14% of the world’s population, according to the World Health Organization (WHO). These disorders may occur from birth or gradually develop over time.

Factors that can increase a person’s susceptibility to hearing disorders include genetic predispositions, advanced age, frequent exposure to loud noises and some infectious diseases.

Measles, rubella and meningitis are examples of infectious diseases that can lead to hearing loss. A lack of access to vaccines that prevent these diseases remains a major obstacle for millions of people living in impoverished environments around the world. In recent years, however, measles outbreaks have even affected developed countries such as the US, UK, New Zealand and Israel.

Reluctance or refusal to receive vaccinations against infectious diseases is becoming a widespread issue in communities where distrust of scientific information is prevalent. Reasons for vaccine hesitancy include the belief that vaccines are harmful or ineffective in preventing the contraction of contagious diseases.

Hearing-related health consequences of infectious diseases can be caused by inflammation of the eardrum and damage to the auditory nerve. The physical symptoms of hearing loss are not the only source of distress for patients. Common psychosocial difficulties include loneliness, depression and anxiety.

These issues are often caused by the inability of sufferers to communicate with other people. Children with untreated hearing loss may suffer from a decreased ability to complete schoolwork and develop problems with socialising with peers.

Families who fail to adhere to childhood immunisation programmes are punished in some countries, but mandatory vaccination policies are difficult to enforce and can cause further distrust of healthcare services and medical professionals.

One of the most important benefits of mass vaccination is the concept of herd immunity. In herd immunity, a large percentage of the population is resistant to a particular disease-causing agent. This indirectly protects people who are immunocompromised or otherwise unable to receive a vaccination for a particular communicable disease.

Another leading cause of hearing loss in young infants is cytomegalovirus infection, which rarely impacts healthy adults but can cross the placenta and cause disease in a growing fetus. As of this month, a number of messenger RNA vaccines are being developed by Moderna to prevent CMV infection.

Outbreaks of infectious diseases that can be controlled through the effective implementation of immunisation programs present a current threat to the wellbeing of vulnerable individuals. It is therefore of critical importance that people are made aware of how straightforward it can be to prevent the destruction that infectious diseases can inflict on the sensory organs.

For pharmaceutical industry data, comment and analysis, visit GlobalData's Pharmaceuticals Intelligence Centre.

Go to article: Home | Antibiotic AdjacentGo to article: In this issueGo to article: ContentsGo to article: SHL Company InsightGo to article: SHL MedicalGo to article: TiveGo to article: Controlant Company InsightGo to article: ControlantGo to article: BriefingGo to article: Industry newsGo to article: The pharma industry briefingGo to article: Covid-19 executive briefing by GlobalDataGo to article: Mimotopes Company Insight Go to article: MimotopesGo to article: L.B. Bohle MaschinenGo to article: L.B Bohle Company InsightGo to article: ACG WorldwideGo to article: CommentGo to article: HPV infections drop due to widespread vaccinationGo to article: Europe reports the highest prevalence of chronic cough across the 7MMGo to article: How could vaccine hesitancy affect the prevalence of hearing disorders?Go to article: Datwyler Company Insight Go to article: DatwylerGo to article: RegPakGo to article: PfeifferGo to article: In DepthGo to article: Antibiotic adjacent: the alternatives tackling AMR Go to article: Regenerative medicine: ready for the big leagues? Go to article: Human challenge trials: pandemic exit strategy or ethical nightmare?Go to article: Drug dispensing goes digitalGo to article: Could this Novartis initiative finally cure sickle cell disease?Go to article: Centessa Pharmaceuticals: forging a new path for pharma R&DGo to article: Biomax Company InsightGo to article: BiomaxGo to article: DuojectGo to article: Duoject Company InsightGo to article: In DataGo to article: Deals analysisGo to article: The pharma industry key listGo to article: Global markets and indicesGo to article: Macro-economic indicatorsGo to article: Macro-economic indicators (page 2)Go to article: The Solubility Company - Company Insight Go to article: The Solubility companyGo to article: MyonexGo to article: BaxterGo to article: EventsGo to article: Next issue